Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy to host its first ESMO Fellowship Awardee
Gustave Roussy will host its first ESMO European Integration Fellowship Awardee, who will be trained by Dr. Alexandra Leary in the Gynecological Department.
Published on
Gustave Roussy will host its first ESMO European Integration Fellowship Awardee, who will be trained by Dr. Alexandra Leary in the Gynecological Department.
Dr. Milan Paul Kubelac from Romania is the first to organize his traineeship, and selected Gustave Roussy as his first choice. He is interested in gynecological oncology with a focus on ovarian cancer that is resistant to standard platinum-based therapy.
The ESMO European Integration Fellowship is a pilot program that was launched in 2016 to allow oncologists from lower and middle-income countries to gain first-hand experience at a leading European Cancer Center. The six-week specialized training program is being adapted by Drs. Alexandra Leary, Suzette Delaloge, and colleagues to match Dr. Kubelac’s needs.
Both Gustave Roussy and Dr. Kubelac will receive financial support from ESMO to cover costs of the six-week training to begin in June 2017.
To learn more about the ESMO fellowship program
Last news
-
Nuclear medicine: DART, a pioneering platform for the development of alpha therapy
Developed through a partnership between Gustave Roussy and the Paris-Saclay Cancer Cluster, the DART project aims to provide industry partners with a centre of excellence spanning preclinical, clinical and translational research to support the development of alpha therapy. This innovative nuclear medicine approach can destroy cancer cells more powerfully than standard approaches while reducing damage to surrounding healthy cells.
-
Gustave Roussy at the ESMO 2026 Congress
The European Society for Medical Oncology (ESMO) is holding its annual congress from 23 to 27 October in Madrid, Spain. This major international event provides oncologists and researchers from around the world with an opportunity to present the latest findings from clinical studies aimed at improving cancer care and deepening our understanding of the disease. Once again, this year, physicians and researchers from Gustave Roussy have contributed to several dozen studies that will be presented during the five-day congress.
-
5 questions with Dr François-Xavier Danlos about therapeutic cancer vaccines
Therapeutic cancer vaccines are making significant progress in clinical development. The ESMO Congress, which begins on 23 October, will provide an opportunity to learn about new data on a therapeutic vaccine against melanoma. However, there are major differences between vaccines traditionally used to prevent disease and therapeutic cancer vaccines. Dr François-Xavier Danlos, a medical oncologist in Gustave Roussy’s Drug Development Department and a specialist in immunotherapy development, explains.
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
